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tion of donor T cells into the lung. To examine the effect of these
chemokines on T cell recruitment, we treated allogeneic recipients
with polyclonal antibodies (Abs) against MIG and IP-10 or control
from day 0 until day 28. Lung pathology at day 28 was signiﬁcantly
decreased in the Ab-treated animals and was associated with sig-
niﬁcantly decreased numbers of total cells, CD8T cells and
TNFa levels in the BAL ﬂuid (table 1). MIG/IP-10 neutralization
also resulted in reduced damage to the GI tract by week 1 and 4
(table 1), whereas liver pathology was unaffected. Clinical GVHD
scores were also lower in Ab-treated animals at weeks 5 and 6 after
SCT and correlated with a reduction in mortality during this time.
In a ﬁnal set of experiments, we used CXCR3-/- mice as allo SCT
donors and found that mice receiving CXCR3-/- cells had de-
creased lung injury compared to allo wild-type controls at week 4
as measured by BAL cellularity (1.2  0.1 vs. 2.5  0.4 mio),
CD8T cells (0.06  0.01 vs. 0.17  0.03 mio) and TNFa levels
(9.0  1.8 vs. 33.4  8.0 pg/ml). In conclusion, our data demon-
strate, that interactions between the chemokines MIG and IP-10
and their receptor CXCR3 are important for donor T cell recruit-
ment into the lung and the development of IPS. Approaches
focusing on the abrogation of these interactions may prove suc-
cessful in preventing or treating this serious complication after
allogeneic SCT.
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DONOR LEUKOCYTE-PRODUCTION OF RANTES SIGNIFICANTLY CON-
TRIBUTES TO THE DEVELOPMENT OF IDIOPATHIC PNEUMONIA SYN-
DROME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Hildebrandt, G.C.1, Olkiewicz, K.M.1, Corrion, L.C.1, Liu, C.2, Cooke,
K.R.1 1. Dept. of Pediatrics; BMT Program, University of Michigan,
Ann Arbor, MI; 2. Dept. of Pathology; University of Florida School of
Medicine, Gainesville, FL
Idiopathic pneumonia syndrome (IPS) is a major cause of mor-
tality after allogeneic (allo) stem cell transplantation (SCT). IPS
pathophysiology includes the secretion of inﬂammatory cyto- and
chemokines along with the recruitment of donor T cells and
monocytes/macrophages. We hypothesized that leukocyte recruit-
ment during IPS is dependent, at least in part, upon interactions
between RANTES and its primary receptor CCR5: RANTES is
produced predominantly by CD8 T cells, epithelium, and ﬁbro-
blasts and promotes CCR5 T cell and macrophage inﬁltration to
inﬂammatory sites. Using an established mouse SCT model, le-
thally irradiated B6DF1 mice received SCT from syngeneic
(B6D2F1) or allogeneic (B6) donors. Pulmonary CCR5 mRNA
expression was signiﬁcantly increased from week 1 to week 6 in allo
SCT recipients compared to syngeneic controls and correlated
with donor effector cell recruitment to the lung and increasing
histopathology scores over time. Pulmonary RANTES mRNA
expression was signiﬁcantly increased from week 1 to 6 after allo
SCT and correlated with increases in BAL ﬂuid protein levels at
weeks 2 (277.7  21.2 vs 18.2  18.2 pg/ml) and 6 (103.3  40.1
vs 0.8  0.8 pg/ml). Furthermore, percentages of RANTES se-
creting CD4 and CD8 T cells were signiﬁcantly increased in
lungs of allo SCT recipients by week 2 after transplant (CD4:
14.8  5.5 vs 0.7  0.2; CD8: 17.2  5.9 vs 0.6  0.2). This
suggested that RANTES production from donor effector cells
contributes to the evolution of IPS. We next used wild type (wt) or
RANTES-/- mice as allo SCT donors. Lung injury after RAN-
TES-/- SCT was signiﬁcantly reduced by week 6 compared to wt
controls and was associated with decreases in total BAL cellularity
and in numbers of CD8 and CD4 T cells (Table 1). Although
survival (wt: 54% vs RANTES-/-: 66%) and clinical GVHD score
(wt: 4.8  0.4 vs RANTES-/-: 4.1  0.4) were not different
between groups, injury to GI tract and liver was decreased after
RANTES-/- SCT (Table 1). We next completed mixing experi-
ments wherein wt or RANTES-/- bone marrow was supplemented
with either wt or RANTES-/- T cells and found that RANTES
from both cellular sources contributes to IPS. Collectively, these
data demonstrate that RANTES production by donor leukocytes is
important to the development of lung, intestinal and hepatic dam-
age after allo SCT and suggest that strategies which disrupt
RANTES:CCR5 interactions may be helpful in treating or pre-
venting IPS and target organ GVHD.
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ANTIBODY RESPONSE TO H-Y MINOR HISTOCOMPATIBILITY ANTI-
GENS CORRELATES WITH CHRONIC GRAFT VERSUS HOST DISEASE AND
DISEASE REMISSION
Miklos, D.B., Kim, H.T., Miller, K.H., Guo, L., Zorn, E., Hochberg,
E.P., Lee, S.J., Soiffer, R.J., Antin, J.H., Ritz, J. Dana-Farber Cancer
Institute, Boston, MA
H-Y antigens are important targets of graft versus host disease
(GVHD) and graft versus leukemia in male patients who receive
hematopoietic stem cell transplants from female donors (F 3 M
HSCT). In previous studies, we demonstrated that male patients
who receive stem cells from female donors (F 3 M HSCT)
frequently develop antibody responses to H-Y antigen DBY. To
determine whether other Y-chromosome encoded proteins elicit
B-cell immune responses in F 3 M HSCT, we developed ELISA
for 5 H- Y antigens: DBY, UTY, ZFY, RPS4Y and EIF1AY and
their respective X-homologues. Serum samples from 125 HSCT
patients and 136 normal donors were tested (Table below). Over-
all, 51% of male patients with female donors developed antibody to
at least 1 H-Y antigen compared to 18% with antibody to any H-X
homolog (p  0.001). All H-X responders were also H-Y respond-
ers, and the magnitude of each H-Y response was greater than the
corresponding H-X response. Normal males and M 3 M HSCT
patients rarely had antibody detected for any H-Y antigen, how-
ever 41% of females had antibody detected for at least one H-Y
antigen. F3MHSCT serial samples revealed: 1) antibody to H-Y
antigens were absent pre-HSCT, 2) DBY antibody developed 4-8
months post-HSCT either concurrently or before UTY, ZFY, and
RPS4Y antibodies, and 3) each H-Y antibody response persisted
for at least two years post-HSCT. In order to explore the clinical
signiﬁcance of B-cell response to H-Y antigens, we measured 66
well-characterized F3MHSCT patients six months to two years
post-HSCT with our novel ﬁve H-Y antigens ELISA panel and
correlated these results with clinical outcome. The overall inci-
dence of limited or extensive cGVHD in this cohort was 53%. The
presence of an antibody response to 1 or more H-Y antigens was
highly signiﬁcantly correlated with the development of cGVHD
(p  0.001), and persistent disease remission (p  0.001). Logistic
regression models examining donor age, patient age, unrelated
donor, HLA-mismatched donor, stem cell source, disease, T cell
depletion, or nonmyeloablative conditioning failed to establish
association of these risk factors with either cGVHD or H-Y sero-
Table.
Lung
Path.
Total
BAL
Cells
(mio.)
BAL CD8
Cells (mio.)
BAL
TNF
(pg/mL)
Gut
Path.
Week 1
Gut Path.
Week 4
Synctrl 1.40.4 0.60.04 0.040.003 6.90.1 8.00.6 13.01.0
Alloctrl 5.30.4 1.60.38 0.190.047 20.83.2 23.21.6 19.52.3
Alloanti-
MIG/IP-
10 3.50.4* 0.40.04* 0.020.002* 7.83.0* 13.81.6* 13.21.6 ()
*P  .05; () P  .06.
Table.
Group
Lung
Path.
BAL
Cellularity
(mio.)
BAL
CD8
(mio.)
BAL
CD4
(mio.)
GI Tract
Path.
Liver
Path.
Syngeneic 0.2  0.1 0.7  0.3 0.01  0.01 0.1  0.1 4.6  0.8 1.6  0.3
Allo wt 5.3  0.6 2.5  0.2 0.7  0.1 0.5  0.1 14.0  0.8 14.1  1.0
Allo
RANTES/
2.5  0.5* 0.8  0.2* 0.3  0.1* 0.3  0.1 10.6  1.4* 8.6  0.7*
*P  .05.
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